Clinical trials: Adenocarcinoma of Rectum
Locally Advanced Rectal Carcinoma
Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer
The aim of this clinical trial is to compare triplet induction therapy (FOLFOXIRI) with doublet induction therapy (CAPOX/FOLFOX), followed by chemoradiotherapy and either surgery or a watch-and-wait approach, in patients with…
- Trial name
- MEND-IT II (NCT07472868)
- Testing
- FOLFOXIRI, CAPOX, FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)
- Where
- 20 sites in Netherlands
- Volunteers
- 394 people
- Sponsor
- J. W. A. Burger
Early Rectal Cancer, Stage I Rectal Cancer
RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer
This is a multi-site, prospective, non-randomized phase 2 study evaluating neoadjuvant botensilimab in combination with balstilimab for patients with microsatellite stable (MSS) / mismatch repair proficient (MMRp) early rectal…
- Conditions
- Early Rectal Cancer, Stage I Rectal Cancer, Microsatellite Stable Rectal Carcinoma
- Trial name
- RECTIFY-1 (NCT07735624)
- Testing
- Botensilimab, Balstilimab
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Dana-Farber Cancer Institute
Rectal Neoplasms
Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma
The investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or…
- Trial name
- OPERA (NCT02505750)
- Testing
- 3D conformal EBRT, Contact X-ray brachytherapy 50 kV, Capecitabine
- Where
- 18 sites in France, Switzerland and 1 more
- Volunteers
- 148 people
- Sponsor
- Centre Antoine Lacassagne
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Biological therapies such as erlotinib may interfere with the growth of tumor cells and slow the growth of the tumor. Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or metastatic…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT00032110
- Testing
- erlotinib hydrochloride, pharmacological study, laboratory biomarker analysis
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Relationship Between Quality of Life, Treatment Modalities, and Patient Treatment/Outcome Expectations
The goal of this study is to learn how the treatment given to patients with recurrent rectal cancer affects their well being and quality of life.
- Trial name
- NCT00648635
- Testing
- Questionnaire
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer
Follow-Up Care With or Without CEA Assessments in Patients Who Have Undergone Surgery for Stage II or Stage III Colorectal Cancer
RATIONALE: Diagnostic procedures, such as ultrasound, x-ray, colonoscopy, CT scan, and CEA assessment, may help monitor a patient's response to surgery.
- Trial name
- SURVEILLANCE (NCT00995202)
- Testing
- Standard Monitoring CEA, Intensive Monitoring CEA, Standard Monitoring Imagery
- Where
- 117 sites in Belgium, France and 1 more
- Volunteers
- 1,997 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Colorectal Cancer, Metastatic Cancer
Combination Chemotherapy Before or After Surgery in Treating Patients With Colorectal Cancer With Liver Metastases That Could Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy work in different ways to kill tumor cells or stop them from growing. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that…
- Trial name
- NCT01189227
- Testing
- Postoperative chemotherapy, Perioperative chemotherapy
- Where
- 283 sites in United States
- Volunteers
- 9 people
- Sponsor
- NSABP Foundation Inc
Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8
Evaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal Cancer
This study evaluates quality of life and utilities following surgical treatment of stage I-IV rectal cancer. This study may help researches learn more about quality of life in patients who have or have had rectal cancer.
- Conditions
- Rectal Adenocarcinoma, Stage I Rectal Cancer AJCC v8, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8
- Trial name
- NCT02107105
- Testing
- Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 430 people
- Sponsor
- M.D. Anderson Cancer Center
Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8
An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer
This early phase I trial investigates how well 64Cu-labeled M5A antibody scan works in assessing tumor activity before and after patients with rectal cancer that has spread to nearby tissue or lymph nodes (locally advanced) who…
- Conditions
- Locally Advanced Rectal Carcinoma, Stage III Rectal Cancer AJCC v8, Stage IIIA Rectal Cancer AJCC v8, Stage IIIB Rectal Cancer AJCC v8
- Trial name
- NCT05245786
- Testing
- Copper Cu 64 Anti-CEA Monoclonal Antibody M5A, Imaging Technique
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- City of Hope Medical Center
Rectal Carcinoma
PET/MRI as a Predictor of Response to Pre-op Chemoradiation in Resectable Rectal Cancer: a Pilot Study
This is a single arm, single center pilot study of 40 patients with uT3N0 or uT1-3N+ rectal cancer receiving pre-operative chemoradiation. Subjects will undergo PET/MRI scans before and after surgery.
- Trial name
- NCT01751516
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer
Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer
RATIONALE: Rectal reconstruction after surgery to treat rectal cancer may help patients keep some of their bowel function. It is not yet known which method of rectal reconstruction is most effective after surgery.
- Trial name
- NCT00238381
- Testing
- 5 cm colon-J-pouch, side-to-end anastomosis, straight coloanal anastomosis
- Where
- 18 sites in Germany, Switzerland
- Volunteers
- 336 people
- Sponsor
- Swiss Cancer Institute
Rectal Adenocarcinoma, Colon Adenocarcinoma
Audit of Surgery for Colorectal Cancer
The aim of this project is to audit the surgical care in patients treated for colorectal adenocarcinoma. This study focused on collecting data from all consecutive cases of colon and rectal adenocarcinoma operated at the National…
- Trial name
- AuditCR (NCT04349384)
- Testing
- Colorectal resection
- Where
- Morocco
- Volunteers
- 136 people
- Sponsor
- Institut National d'Oncologie, Morocco
Colorectal Cancer
FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum
This is a randomized phase II study trial that has served as a screening trial to test the increased efficacy of chemotherapy + cetuximab versus chemotherapy alone among patients with untreated, advanced or metastatic colon…
- Trial name
- NCT00077233
- Testing
- cetuximab, 5-FU, irinotecan
- Where
- 77 sites in United States
- Volunteers
- 238 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II
"Oncologic Results and Risk Factors for Recurrence in Patients With Locally Advanced Rectal Cancer and Pathologic Complete Response After Neoadjuvant Treatment. Results From an Observational Retrospective Multicenter Long-term Follow-up Study".
Pathologic complete response (pCR) after multimodal treatment for locally advanced rectal cancer (LARC) patients is considered as the gold-standard of treatment success as it is associated to privileged oncologic outcome.
- Conditions
- Rectal Cancer, Adenocarcinoma, Rectal Cancer Stage II, Rectal Cancer Stage III, Distant Metastasis
- Trial name
- NCT05495308
- Testing
- neoadjuvant treatment
- Where
- Spain
- Volunteers
- 4 people
- Sponsor
- Hospital San Carlos, Madrid
Stage II Rectal Cancer, Stage III Rectal Cancer
Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma
The primary objective of the pilot portion of this study is to establish the safety and tolerability of an extended treatment break period in patients who have undergone neoadjuvant chemoradiotherapy as well as use of systemic…
- Trial name
- NCT01302613
- Testing
- Capecitabine, 5-FU, Leucovorin
- Where
- United States
- Sponsor
- University of Texas Southwestern Medical Center
Rectal Adenocarcinoma, Rectal Cancer
Asian Watch-and-Wait Database (AWWD)
The standard treatment approach of localized rectal adenocarcinoma involves neoadjuvant radiotherapy and chemotherapy followed by assessment for surgery and optional adjuvant chemotherapy.
- Trial name
- AWWD (NCT06631443)
- Where
- India
- Volunteers
- 337 people
- Sponsor
- Tata Memorial Centre
Colorectal Cancer
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Previously Treated With Irinotecan
Phase II trial to study the effectiveness of combining oxaliplatin, fluorouracil and leucovorin in treating patients who have metastatic colorectal cancer that has been previously treated with irinotecan.
- Trial name
- NCT00016978
- Testing
- FOLFOX regimen, fluorouracil, leucovorin calcium
- Where
- 24 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Fecal Incontinence, Quality of Life
Value of Anorectal Manometry Before Ileo- or Sigmoidostomy Closure After Rectal Resection
Background: High prevalence of fecal incontinence after rectal resection in patients with rectal carcinoma. Hypothesis: Anorectal manometry done before ileostomy or sigmoidostomy closure can predict fecal incontinence.
- Trial name
- NCT02196597
- Where
- 3 sites in Germany
- Volunteers
- 30 people
- Sponsor
- German Society for Neurogastroenterology and Motility
Rectal Cancer
IPC Status as a Surgical Quality Marker in Rectal Cancer Surgery
Risk of local recurrence after rectal surgery is nationally 8% after curative surgery to 5%. Local recurrence rate after curative surgery varies between 3-7% in the variety of regions in the country.
- Trial name
- NCT02081547
- Where
- 2 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- Uppsala University
Adenocarcinoma of the Lower Rectum
Non-Operative Management and Early Response Assessment in Rectal Cancer
The investigators' data from a phase I study of short course radiation therapy followed by chemotherapy showed 74% complete clinical response (cCR).
- Trial name
- NOM-ERA (NCT03904043)
- Testing
- Radiation therapy, FOLFOX regimen, CAPOX regimen
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Washington University School of Medicine